Search results
Oct 19, 2024 · 4. Radiation and radioligand therapy in mCRPC. ARPIs are relatively well tolerated and are thus ideal candidates for combination therapy. This is true for pharmacological therapy, with triplet therapy approved for metastatic HSPC and combination PARP inhibitor therapy approved for mCRPC.
Oct 23, 2024 · The radioligand therapy 177 Lu-PNT2002 led to an improvement in radiographic progression-free survival (rPFS) vs an androgen receptor pathway inhibitor (ARPI) in patients with prostate-specific...
4 days ago · In 3 clinical trials investigating the use of androgen receptor pathway inhibitors (ARPIs) in nonmetastatic castration-resistant prostate cancer (nmCRPC), the primary endpoint of metastases-free...
5 days ago · Why Words Matter in Advanced Prostate Cancer. William K. Oh. Corresponding authors. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029, USA. Tel. +1 212 659 5429; Fax: +1 212 659 8539 (W.K. Oh). Huntsman Cancer Institute at the University of Utah, 2000 Circle of Hope, Salt Lake City, UT ...
Oct 9, 2024 · The study's real-world evidence aligns with phase 3 trial results, offering insights into ARPI effectiveness without direct comparator trials.
Oct 10, 2024 · The PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi), an androgen receptor pathway inhibitor (ARPI), led to statistically significant and meaningful improvements in overall survival (OS) in all-comers as well as patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer ...
5 days ago · The study included 468 taxane-naive mCRPC patients who were prostate-specific membrane antigen (PSMA)-positive on [68 Ga]Ga-PSMA-11 PET/CT imaging and candidates for an ARPI change after one progression on prior ARPI therapy.
